Technical Difficulties Prevented Priority Review Of GSK Melanoma Drugs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline withdrew priority review requests for its high-profile melanoma drugs Mekinist and Tafinlar as extensive problems with both the quality of the NDA data and the statistical analysis software in the electronic submissions emerged. Statistical reviewers called out sponsor for inadequate response to problems, wasting time.